1240390-33-3

Basic information

• Product Name: 1,5-anhydro-2-((tert-butoxycarbonyl)amino)-2,4-dideoxy-L-threo-pentitol
• CAS NO: 1240390-33-3
• Molecular Weight: 217.265
• Mol File: 1240390-33-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1,5-anhydro-2-((tert-butoxycarbonyl)amino)-2,4-dideoxy-L-threo-pentitol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,5-anhydro-2-((tert-butoxycarbonyl)amino)-2,4-dideoxy-L-threo-pentitol(1240390-33-3)
• EPA Substance Registry System: 1,5-anhydro-2-((tert-butoxycarbonyl)amino)-2,4-dideoxy-L-threo-pentitol(1240390-33-3)

Safety Data

• Hazardous Substances Data: 1240390-33-3(Hazardous Substances Data)

Usage

Chemical class

Pentitols

Synthetic compound

Yes

Used in

Organic chemistry research and drug synthesis

Molecular weight

247.28 g/mol

Physical state at room temperature

White solid

Storage conditions

Dry and cool environment to prevent degradation

Common use

Starting material in the synthesis of various drugs and pharmaceuticals

Unique features

Unique structure and reactivity

Upstream product

• 25637-16-5 4-bromotetrahydro-2H-pyran 
• 3174-74-1 dihydropyran 
• 286-22-6 3,4-epoxytetrahydropyran 
• 1240390-30-0 (3S,4S)-3-((S)-1-phenylethylamino)tetrahydro-2H-pyran-4-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1309081-45-5 (3R,4R)-3-aminotetrahydro-2H-pyran-4-ol 
• 1240390-32-2 2-amino-1,5-anhydro-2,4-dideoxy-L-threo-pentitol 

Downstream Products

• 1240390-36-6 tert-butyl ((3R,4R)-4-aminotetrahydro-2H-pyran-3-yl)carbamate 
• 1439909-39-3 tert-butyl ((3R,4R)-4-((5-carbamoyl-4-((3-chlorophenyl)amino)pyrimidin-2-yl)amino)tetrahydro-2H-pyran-3-yl)carbamate 
• 1439906-07-6 2-(((3R,4R)-3-aminotetrahydro-2H-pyran-4-yl)amino)-4-((3-chlorophenyl)amino)pyrimidin-5-carboxamide 

Relevant articles and documents

FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF

Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.

SELECTIVE KINASE INHIBITORS

Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.